Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers

J. Stuart Ferriss, M. Yvette Williams-Brown

Research output: Contribution to journalReview article

Abstract

Research into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that two of the most common gynecologic cancers in the USA have strong biologic rationales for response to these agents. Work is now underway to demonstrate safe and effective therapies for our patients. As we better understand the immune system, and more specifically the tumor microenvironment, we will be able to achieve complete responses. The immune system can learn, adapt, and provide ongoing surveillance; if only we could mimic its abilities.

Original languageEnglish (US)
Article number75
JournalCurrent treatment options in oncology
Volume20
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Immunotherapy
Immune System
Neoplasms
Tumor Microenvironment
Therapeutics
Research

Keywords

  • Checkpoint inhibitors
  • Endometrial cancer
  • Gynecologic cancers
  • Immunotherapy
  • Lynch syndrome
  • Ovarian cancer
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Immunotherapy : Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers. / Ferriss, J. Stuart; Williams-Brown, M. Yvette.

In: Current treatment options in oncology, Vol. 20, No. 10, 75, 01.10.2019.

Research output: Contribution to journalReview article

@article{7ecdd2df26f84ea681b4c6b9c323866c,
title = "Immunotherapy: Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers",
abstract = "Research into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that two of the most common gynecologic cancers in the USA have strong biologic rationales for response to these agents. Work is now underway to demonstrate safe and effective therapies for our patients. As we better understand the immune system, and more specifically the tumor microenvironment, we will be able to achieve complete responses. The immune system can learn, adapt, and provide ongoing surveillance; if only we could mimic its abilities.",
keywords = "Checkpoint inhibitors, Endometrial cancer, Gynecologic cancers, Immunotherapy, Lynch syndrome, Ovarian cancer, PD-1, PD-L1",
author = "Ferriss, {J. Stuart} and Williams-Brown, {M. Yvette}",
year = "2019",
month = "10",
day = "1",
doi = "10.1007/s11864-019-0676-8",
language = "English (US)",
volume = "20",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Immunotherapy

T2 - Checkpoint Inhibitors in Lynch-Associated Gynecologic Cancers

AU - Ferriss, J. Stuart

AU - Williams-Brown, M. Yvette

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Research into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that two of the most common gynecologic cancers in the USA have strong biologic rationales for response to these agents. Work is now underway to demonstrate safe and effective therapies for our patients. As we better understand the immune system, and more specifically the tumor microenvironment, we will be able to achieve complete responses. The immune system can learn, adapt, and provide ongoing surveillance; if only we could mimic its abilities.

AB - Research into novel therapies for gynecologic cancers is underfunded, and as a result, we are still playing catchup with other solid tumors in the realm of immune checkpoint inhibition. This is despite the fact that two of the most common gynecologic cancers in the USA have strong biologic rationales for response to these agents. Work is now underway to demonstrate safe and effective therapies for our patients. As we better understand the immune system, and more specifically the tumor microenvironment, we will be able to achieve complete responses. The immune system can learn, adapt, and provide ongoing surveillance; if only we could mimic its abilities.

KW - Checkpoint inhibitors

KW - Endometrial cancer

KW - Gynecologic cancers

KW - Immunotherapy

KW - Lynch syndrome

KW - Ovarian cancer

KW - PD-1

KW - PD-L1

UR - http://www.scopus.com/inward/record.url?scp=85071266236&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071266236&partnerID=8YFLogxK

U2 - 10.1007/s11864-019-0676-8

DO - 10.1007/s11864-019-0676-8

M3 - Review article

C2 - 31444655

AN - SCOPUS:85071266236

VL - 20

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 10

M1 - 75

ER -